Differences between Hyperprogressive Disease and
Progressive Disease in Patients Receiving Immunotherapy

Objectives: Although immune checkpoint inhibitors (ICIs) became a vital part of cancer care, many patients do not respond to treatment. In this group, a few of the patients with a hyperprogressive disease (HPD) have shorter overall survival (OS) compared with those having a progressive disease (PD). Therefore, biomarkers are needed to differentiate HPD and PD. Methods: Ninety-five patients treated with ICIs with progression according to response evaluation criteria ın solid tumors criteria in the first control imaging were included. HPD was defined according to Russo's work. The PILE scoring system, which includes pan-immune-inflammation value, lactate dehydrogenase, and Eastern Cooperative Oncology Group PS, was followed. The relationship between PILE score and HPD was analyzed. Results: The median OS of all cohorts was 11.18 months. The patients in the HPD group had decreased OS (4.77 vs. 13.94 months, p<0.001) and progression-free survival (PFS) (1.89 vs. 3.16 months, p<0.001) compared with those in the PD group. The risk of HPD was higher than the risk of PD in patients with a high PILE score (p=0.001). Conclusion: In this study, we showed that patients treated with ICI with a higher PILE score are at greater risk for HPD. The PILE score may be a biomarker to differentiate HPD from PD.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Borcoman E, Kanjanapan Y, Champiat S, Kato S, Servois V, Kurzrock R, et al. Novel patterns of response under immunotherapy. Ann Oncol 2019;30:385–96.
2. Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/ PD-L1. Clin Cancer Res 2017;23:1920–8.
3. Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PDL1 inhibitors or with single-agent chemotherapy. JAMA Oncol 2018;4:1543–52.
4. Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, et al. Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. Cancer 2019;125:1341–9.
5. Kim CG, Kim KH, Pyo KH, Xin CF, Hong MH, Ahn BC, et al. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann Oncol 2019;30:1104–13.
6. Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti- PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2017;28:1605–11.
7. Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, et al. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer 2019;22:793–802.
8. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res 2017;23:4242–50.
9. Matos I, Martin-Liberal J, Hierro C, De Olza MO, Viaplana C, Costa M, et al. Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials. J Clin Oncol 2018;36:3032.
10. Lo Russo G, Moro M, Sommariva M, Cancila V, Boeri M, Centonze G, et al. Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade. Clin Cancer Res 2019;25:989–99.
11. Tunali I, Gray JE, Qi J, Abdalah M, Jeong DK, Guvenis A, et al. Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report. Lung Cancer 2019;129:75–9.
12. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al; KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078–92.
13. Paz-Ares L, Luft A, Vicent D, Tafreshi A, Gümüş M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non– small-cell lung cancer. N Engl J Med 2018;379:2040–51.
14. Larkin J, Sileni VC, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23–34.
15. Ge X, Zhang Z, Zhang S, Yuan F, Zhang F, Yan X, et al. Immunotherapy beyond progression in patients with advanced nonsmall cell lung cancer. Transl Lung Cancer Res 2020;9:2391– 400.
16. Viñal D, Gutierrez-Sainz L, Martinez D, Garcia-Cuesta JA, Pedregosa J, Villamayor J, et al. Prognostic value of neutrophil- to-lymphocyte ratio in advanced cancer patients receiving immunotherapy. Clin Transl Oncol 2021;23:1185–92.
17. Bilen MA, Martini DJ, Liu Y, Shabto JM, Brown JT, Williams M, et al. Combined effect of sarcopenia and systemic inflammation on survival in patients with advanced stage cancer treated with immunotherapy. Oncologist 2020;25:528–35.
18. Guven DC, Yildirim HC, Bilgin E, Aktepe OH, Taban H, Sahin TK, et al. PILE: a candidate prognostic score in cancer patients treated with immunotherapy. Clin Transl Oncol 2021;23:1630– 6.
19. Zeng R, Liu F, Fang C, Yang J, Luo L, Yue P, et al. PIV and PILE score at baseline predict clinical outcome of anti-PD-1/PD-L1 inhibitor combined with chemotherapy in extensive-stage small cell lung cancer patients. Front Immunol 2021;12:724443

APA	Yildirim H, GÜVEN D, Aktepe O, TABAN H, YILMAZ F, Yaşar S, Aktaş B, Guner G, Dizdar O, AKSOY S, erman m, yalcin s, Kılıçkap S (2022). Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy. , 59 - 63. 10.14744/ejmo.2022.78280
Chicago	Yildirim Hasan cagri,GÜVEN Deniz Can,Aktepe Oktay Halit,TABAN HAKAN,YILMAZ Feride,Yaşar Serkan,Aktaş Burak Yasin,Guner Gurkan,Dizdar Omer,AKSOY SERCAN,erman mustafa,yalcin suayib,Kılıçkap Saadettin Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy. (2022): 59 - 63. 10.14744/ejmo.2022.78280
MLA	Yildirim Hasan cagri,GÜVEN Deniz Can,Aktepe Oktay Halit,TABAN HAKAN,YILMAZ Feride,Yaşar Serkan,Aktaş Burak Yasin,Guner Gurkan,Dizdar Omer,AKSOY SERCAN,erman mustafa,yalcin suayib,Kılıçkap Saadettin Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy. , 2022, ss.59 - 63. 10.14744/ejmo.2022.78280
AMA	Yildirim H,GÜVEN D,Aktepe O,TABAN H,YILMAZ F,Yaşar S,Aktaş B,Guner G,Dizdar O,AKSOY S,erman m,yalcin s,Kılıçkap S Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy. . 2022; 59 - 63. 10.14744/ejmo.2022.78280
Vancouver	Yildirim H,GÜVEN D,Aktepe O,TABAN H,YILMAZ F,Yaşar S,Aktaş B,Guner G,Dizdar O,AKSOY S,erman m,yalcin s,Kılıçkap S Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy. . 2022; 59 - 63. 10.14744/ejmo.2022.78280
IEEE	Yildirim H,GÜVEN D,Aktepe O,TABAN H,YILMAZ F,Yaşar S,Aktaş B,Guner G,Dizdar O,AKSOY S,erman m,yalcin s,Kılıçkap S "Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy." , ss.59 - 63, 2022. 10.14744/ejmo.2022.78280
ISNAD	Yildirim, Hasan cagri vd. "Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy". (2022), 59-63. https://doi.org/10.14744/ejmo.2022.78280

APA	Yildirim H, GÜVEN D, Aktepe O, TABAN H, YILMAZ F, Yaşar S, Aktaş B, Guner G, Dizdar O, AKSOY S, erman m, yalcin s, Kılıçkap S (2022). Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy. Eurasian Journal of Medicine and Oncology, 6(1), 59 - 63. 10.14744/ejmo.2022.78280
Chicago	Yildirim Hasan cagri,GÜVEN Deniz Can,Aktepe Oktay Halit,TABAN HAKAN,YILMAZ Feride,Yaşar Serkan,Aktaş Burak Yasin,Guner Gurkan,Dizdar Omer,AKSOY SERCAN,erman mustafa,yalcin suayib,Kılıçkap Saadettin Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy. Eurasian Journal of Medicine and Oncology 6, no.1 (2022): 59 - 63. 10.14744/ejmo.2022.78280
MLA	Yildirim Hasan cagri,GÜVEN Deniz Can,Aktepe Oktay Halit,TABAN HAKAN,YILMAZ Feride,Yaşar Serkan,Aktaş Burak Yasin,Guner Gurkan,Dizdar Omer,AKSOY SERCAN,erman mustafa,yalcin suayib,Kılıçkap Saadettin Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy. Eurasian Journal of Medicine and Oncology, vol.6, no.1, 2022, ss.59 - 63. 10.14744/ejmo.2022.78280
AMA	Yildirim H,GÜVEN D,Aktepe O,TABAN H,YILMAZ F,Yaşar S,Aktaş B,Guner G,Dizdar O,AKSOY S,erman m,yalcin s,Kılıçkap S Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy. Eurasian Journal of Medicine and Oncology. 2022; 6(1): 59 - 63. 10.14744/ejmo.2022.78280
Vancouver	Yildirim H,GÜVEN D,Aktepe O,TABAN H,YILMAZ F,Yaşar S,Aktaş B,Guner G,Dizdar O,AKSOY S,erman m,yalcin s,Kılıçkap S Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy. Eurasian Journal of Medicine and Oncology. 2022; 6(1): 59 - 63. 10.14744/ejmo.2022.78280
IEEE	Yildirim H,GÜVEN D,Aktepe O,TABAN H,YILMAZ F,Yaşar S,Aktaş B,Guner G,Dizdar O,AKSOY S,erman m,yalcin s,Kılıçkap S "Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy." Eurasian Journal of Medicine and Oncology, 6, ss.59 - 63, 2022. 10.14744/ejmo.2022.78280
ISNAD	Yildirim, Hasan cagri vd. "Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy". Eurasian Journal of Medicine and Oncology 6/1 (2022), 59-63. https://doi.org/10.14744/ejmo.2022.78280